Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Statin Studies May Dampen Enthusiasm For Cost-Effectiveness Trials – AARP

Executive Summary

Results of the head-to-head comparison of Pfizer's Lipitor and Bristol-Myers Squibb's Pravachol may reduce industry's enthusiasm for comparative studies, AARP CEO Bill Novelli said

You may also be interested in...



High-Dose Statins IDEAL For Use In High-Risk Patients, Study Suggests

Results of the IDEAL study support the aggressive use of high-dose statins as standard therapy for patients at high risk of repeat cardiovascular events, Scott Grundy (University of Texas Southwestern Medical Center) told the American Heart Association annual meeting Nov. 15 in Dallas

High-Dose Statins IDEAL For Use In High-Risk Patients, Study Suggests

Results of the IDEAL study support the aggressive use of high-dose statins as standard therapy for patients at high risk of repeat cardiovascular events, Scott Grundy (University of Texas Southwestern Medical Center) told the American Heart Association annual meeting Nov. 15 in Dallas

Bristol Prepares For Life After Pravachol: Support Will Continue Into 2005

Bristol-Myers Squibb will continue to promote Pravachol over the near term despite declining sales for the statin as wholesalers prepare for generic competition in 2006

Related Content

UsernamePublicRestriction

Register

PS043546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel